Cassava Sciences | PTIE - Actif À Court Terme





Actif À Court Terme Changement Date
Abbott USD 25.51B 488M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Biogen USD 9.19B 216.3M 2026-03
Cara Therapeutics USD 31.54M 6.9M 2025-12
Cassava Sciences USD 87.96M 9.74M 2026-03
Eisai JPY 761.64B 79.24B 2026-03
Eli Lilly USD 54.84B 794M 2026-03
Geron USD 498.53M 21.74M 2026-03
J&J USD 59.17B 3.55B 2026-03
Merck USD 35.02B 8.5B 2026-03
Novartis USD 26.61B 3.85B 2026-03
Novavax USD 850.82M 127.46M 2026-03
Pfizer USD 42.82B 76M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12